Investing
1469 Articles
A state appeals court in Pennsylvania has sided with two women who filed suit against drugmaker Pfizer Inc. (NYSE: PFE)…
For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at…
As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow…
The lineup of the Dogs of the Dow, simply the ten highest dividend yield stocks of the thirty Dow Jones…
Throughout December we have been giving updates on dividends that will rise in the coming days and weeks from the…
Spending on advertising barely showed a pulse in the third quarter of 2011, growing by just 0.4%, according a report…
Congress, close to a budget agreement, may avoid a government shutdown. (Reuters) Washington Mutual shareholders and creditors set a deal…
We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks…
S&P may downgrade the EU and the largest eurozone banks. (Reuters) France and Germany continue to press new eurozone treaty measures…
Dividends are still rising and equity and income investors should expect more of the same for 2012. The Walt Disney Company…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has had its share of trouble in 2011, but perhaps the expiring patent on…
It has been a long time coming, and now many patients will be able to switch to a generic. Pfizer…
The EU continues to work on its bailout fund and may ask the IMF for help. (Reuters) American Airlines parent…
Pfizer Inc. (NYSE: PFE) has a big day ahead of it. While it has been known for years, it is…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1…
Our top personal finance-related articles today. Your wallet will thank you later.